On the stock market since 2005, it operates in the world of health and science. It has 1,300 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 18% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Sales are growing strongly for its sector.
Clearly above the class average — a step short of the very top.
No real weak spot in any of the five subjects — a balanced report card.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 68% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 17% a year on average.
The company sells $534.5M a year; the problem isn’t sales — it’s costs running above that number.
There is $167.4M in the vault; even if every debt were paid off, $79.4M would remain.
A loss of $11.4M against $534.5M in annual sales.
On our five-subject report card, ATRC sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ATRC has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.